Is Overall Survival Better with Radiofrequency Ablation or Cryoablation for Localized HCC?
No significant difference in overall survival (OS) and liver cancer-specific survival (LCSS) was found in patients with localized hepatocellular carcinoma (HCC) treated with either cryoablation (cryo) or radiofrequency ablation (RFA), according to a study published in Anticancer Research.
This retrospective review utilized the Surveillance, Epidemiology and End Results (SEER) database to find a cohort of patients with Stage 1 or 2 HCC treated with cyro or RFA from 2004-2013.
In the 3239 patients identified, a significant survival advantage in LCSS was found in patients treated with RFA compared with those treated with cryo (HR = 1.634 P = 0.0004). There were 91 propensity-matched pairs with similar OS (HR = 1.006 P = 0.9768). There was no difference in LCSS observed between those treated with RFA and those treated with cryo [HR = 1.412 (95% CI = 0.933 - 2.137) P = 0.1023].
Survival Cox models did not reveal treatment type as an independent prognostic factor.
The authors concluded that, “Propensity-matched cohort showed no significant difference in terms of OS and LCSS was found for patients treated with either cryo or RFA for localized HCC.”
Xu J, Noda C, Erickson A, et al. Radiofrequency Ablation vs. Cryoablation for Localized Hepatocellular Carcinoma: A Propensity-matched Population Study. Anticancer Res. 2018;38(11):6381-6386. doi: 10.21873/anticanres.12997.